Northwest Biotherapeutics, Inc. (NWBO)

OTCMKTS: NWBO · Delayed Price · USD
0.920
+0.067 (7.82%)
Dec 2, 2022 4:00 PM EST - Market closed
7.82%
Market Cap 898.40M
Revenue (ttm) 1.09M
Net Income (ttm) 56.59M
Shares Out 1.05B
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,683,320
Open 0.881
Previous Close 0.853
Day's Range 0.86 - 0.92
52-Week Range 0.39 - 2.05
Beta 0.17
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2022

About NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.... [Read more]

Industry Biotechnology
Founded 1996
CEO Linda Powers
Employees 19
Stock Exchange OTCMKTS
Ticker Symbol NWBO
Full Company Profile

Financial Performance

Financial Statements

News

NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New Lawsuit

Shares of Northwest Biotherapeutics (OTCMKTS: NWBO ) are in focus on Thursday. NWBO stock is up about 5% on the day and it's got investors' attention with a lawsuit against Citadel Securities, among oth...

2 days ago - InvestorPlace

Biotech Company Says Citadel, Other Big Traders Manipulated Its Stock Price

In a new lawsuit, Northwest Biotherapeutics accused market makers of illicit “spoofing” trades.

2 days ago - WSJ

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication    BETHESDA, Md. ,...

2 weeks ago - PRNewsWire

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biot...

3 months ago - PRNewsWire

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Fac...

Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology ...

4 months ago - PRNewsWire

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and ...

BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported...

5 months ago - PRNewsWire

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available O...

BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported...

6 months ago - PRNewsWire

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported ...

6 months ago - PRNewsWire

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...

9 months ago - PRNewsWire

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...

11 months ago - PRNewsWire

Northwest Biotherapeutics Announces $15 Million Financing

BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...

1 year ago - PRNewsWire

3 Biotechs to Avoid Like the Plague in July

Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.

Other symbols: CVMCYDY
1 year ago - The Motley Fool

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...

1 year ago - PRNewsWire

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Other symbols: NVCR
2 years ago - The Motley Fool